401 related articles for article (PubMed ID: 20691300)
1. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
[TBL] [Abstract][Full Text] [Related]
2. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
[TBL] [Abstract][Full Text] [Related]
3. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
[TBL] [Abstract][Full Text] [Related]
4. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
[TBL] [Abstract][Full Text] [Related]
5. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
6. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study).
Tung P; Wiviott SD; Cannon CP; Murphy SA; McCabe CH; Gibson CM
Am J Cardiol; 2009 Apr; 103(8):1056-60. PubMed ID: 19361589
[TBL] [Abstract][Full Text] [Related]
7. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
[TBL] [Abstract][Full Text] [Related]
8. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein levels and outcomes after statin therapy.
Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
[TBL] [Abstract][Full Text] [Related]
10. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
[TBL] [Abstract][Full Text] [Related]
11. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Wiviott SD; Cannon CP; Morrow DA; Ray KK; Pfeffer MA; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1411-6. PubMed ID: 16226163
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Brilakis ES; de Lemos JA; Cannon CP; Wiviott SD; Murphy SA; Morrow DA; Sabatine MS; Banerjee S; Blazing MA; Califf RM; Braunwald E
Am J Cardiol; 2008 Sep; 102(5):552-8. PubMed ID: 18721511
[TBL] [Abstract][Full Text] [Related]
13. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
[TBL] [Abstract][Full Text] [Related]
14. Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
Acharjee S; Qin J; Murphy SA; McCabe C; Cannon CP
Am J Cardiol; 2010 Mar; 105(5):619-23. PubMed ID: 20185006
[TBL] [Abstract][Full Text] [Related]
15. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
[TBL] [Abstract][Full Text] [Related]
16. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease.
Carlquist JF; Muhlestein JB; Horne BD; Hart NI; Bair TL; Molhuizen HO; Anderson JL
Am Heart J; 2003 Dec; 146(6):1007-14. PubMed ID: 14660992
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
18. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
de Grooth GJ; Zerba KE; Huang SP; Tsuchihashi Z; Kirchgessner T; Belder R; Vishnupad P; Hu B; Klerkx AH; Zwinderman AH; Jukema JW; Sacks FM; Kastelein JJ; Kuivenhoven JA
J Am Coll Cardiol; 2004 Mar; 43(5):854-7. PubMed ID: 14998629
[TBL] [Abstract][Full Text] [Related]
19. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
[TBL] [Abstract][Full Text] [Related]
20. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; McCabe CH; Cairns R; Tonkin AM; Sacks FM; Jackson G; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1405-10. PubMed ID: 16226162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]